🔍 Observations
Topline
- Revenue from ops grew 21.4% YoY (₹11,516 Cr → ₹13,980 Cr), reflecting the step-up from an acquired business consolidating into FY26 numbers.
- Q4FY26 printed ₹4,197 Cr — +41.8% YoY and +27.1% QoQ — the sharpest quarterly outturn, indicating the full consolidation effect landed in Q4.
- Other income turned negative in FY26 (–₹94 Cr vs +₹23 Cr), reflecting forex and hedging losses that clipped reported total income.
Bottomline
- Net profit grew 11.9% YoY (₹1,911 Cr → ₹2,138 Cr), well below revenue growth — margin dilution from acquisition-linked D&A and finance costs.
- Q4FY26 net profit collapsed to ₹364 Cr vs ₹498 Cr in Q4FY25 (–26.9% YoY), driven by ₹236 Cr finance costs, ₹508 Cr D&A, and ₹66 Cr exceptional charges in a single quarter.
- Effective tax rate improved to 25.6% (from 28.5%), providing partial offset; without this, PAT growth would have been thinner still.
Margins
- EBITDA margin contracted ~100 bps to 31.3% (FY26) from 32.3% (FY25) — operating leverage partly absorbed by employee cost growth of 21.2% YoY.
- Net profit margin compressed 130 bps to 15.3%, squeezed by D&A surging 40.8% and finance costs up 52.8%.
- Q4FY26 EBITDA margin held at 31.9% (vs 32.0% in Q4FY25) — the operational core is stable; below-EBITDA lines are where the dilution originates.
Growth Trajectory
- Organic revenue growth is likely sub-15%; the headline 21.4% is acquisition-inflated — normalisation will depend on how fast the acquired portfolio integrates.
- EPS grew 13.2% (₹56.47 → ₹63.92) despite no equity dilution — share count unchanged at 169.23 Cr shares — all growth is earnings-driven on the legacy base.
- D&A will remain elevated for multiple years as ₹24,280 Cr of intangible assets amortise; this is the single biggest structural drag on reported PAT growth.
🧮 Profit & Loss Statement
🧮 Balance Sheet
🧮 Cash Flows Statement
🟢 Green Flags
- FCF of ₹2,346 Cr (OCF ₹3,023 Cr minus capex ₹677 Cr) confirms the core business generates substantial cash independent of acquisition noise.
- Q4 revenue of ₹4,197 Cr — 41.8% YoY jump signals the acquired business is a material revenue accretive, not a bolt-on.
- EBITDA margin stability at 31.3%–31.9% across quarters demonstrates operating cost discipline even through an integration year.
- Tax efficiency improved — effective rate fell 290 bps to 25.6%, suggesting deferred tax benefits from the acquisition structure are accruing.
- Dividend payout of ₹1,289 Cr (up 19.0% YoY) signals management confidence in cash generation durability despite elevated debt.
- NCI of ₹9,196 Cr implies partial acquisition of a high-value entity; the remaining minority stake provides a future consolidation pathway.
- Inventory rationalised — inventories contributed a ₹35 Cr inflow to working capital (vs ₹262 Cr outflow in FY25), reflecting tighter supply chain management.
🔴 Red Flags
- Net debt of ₹12,815 Cr at 2.93x EBITDA is a significant leverage event; any EBITDA miss or interest rate increase puts deleveraging timelines at risk.
- Intangibles of ₹24,280 Cr (55% of total assets) — if acquired brands underperform, impairment risk is material and would be non-cash but sentiment-damaging.
- Trade receivables grew 62.3% (₹1,867 Cr → ₹3,031 Cr) against revenue growth of 21.4% — DSO expansion signals collection pressure or channel stuffing risk in acquired geographies.
- Finance costs of ₹385 Cr in FY26 will likely run higher in FY27 as the full-year impact of ₹11,651 Cr long-term borrowings (drawn mid-year) compounds — PAT headwind is not fully visible yet.
- Exceptional charges of ₹89 Cr in FY26 (vs ₹24 Cr prior year) suggest integration costs are mounting; recurrence would further erode reported earnings.
- Other income turned to –₹94 Cr — forex losses on acquisition-related cross-currency exposures add P&L volatility not present in the legacy business.
- Q4 PAT of ₹364 Cr is the weakest quarter despite highest revenue — a quality-of-earnings concern if Q4 cost spikes (D&A ₹508 Cr, finance ₹236 Cr) represent the new quarterly run-rate.
📊 Balance Sheet Analysis
- Total assets tripled (₹14,990 Cr → ₹44,312 Cr) — acquisition-driven; 84% of incremental assets are goodwill and other intangibles, making balance sheet quality contingent on brand value sustainability.
- Equity base doubled to ₹17,585 Cr including ₹9,196 Cr NCI — reported leverage looks manageable at headline, but attributable equity to parent shareholders is only ₹8,389 Cr against net debt of ₹12,815 Cr (net debt/equity of 1.53x on attributable basis).
- Current ratio: Current assets ₹9,392 Cr / Current liabilities ₹8,343 Cr = 1.13x — adequate but thin; short-term borrowings of ₹3,147 Cr represent a refinancing commitment within 12 months.
- Deferred tax liability surged to ₹5,670 Cr (from ₹829 Cr) — acquisition-related intangible amortisation creates timing differences that will convert to cash taxes over time, compressing future FCF.
💰 Cash Flow Analysis
- OCF of ₹3,023 Cr (vs ₹2,585 Cr in FY25, +16.9%) is healthy — despite higher tax outflows of ₹809 Cr — validating that the legacy business cash engine remains intact.
- Investing outflow of ₹12,713 Cr is almost entirely the subsidiary acquisition at ₹12,315 Cr; organic capex of ₹677 Cr is modest and well-covered by OCF.
- Financing inflow of ₹10,151 Cr — ₹10,990 Cr of long-term borrowings raised to fund the acquisition, partially offset by ₹1,289 Cr dividend and ₹427 Cr interest payments — leverage was deliberately taken on, not distress-driven.
- Ending cash of ₹1,117 Cr (vs ₹573 Cr) provides limited buffer relative to short-term debt obligations of ₹3,147 Cr; near-term debt servicing relies on continued strong OCF generation.
💡 Investment Outlook
Torrent Pharma has executed a transformative acquisition in FY26, vaulting revenues past ₹13,900 Cr and adding significant branded portfolio depth — but at the cost of a highly leveraged balance sheet (net debt/EBITDA ~2.9x) and a structurally higher D&A burden from ₹24,280 Cr of intangibles that will suppress reported PAT for years.
The core business remains a high-quality cash compounder — FCF of ₹2,346 Cr and stable EBITDA margins near 31% confirm operational resilience — but the re-rating catalyst now depends on acquired brand revenue scaling faster than amortisation dilutes earnings.
Monitor receivables expansion and Q4’s finance cost run-rate closely; these are the leading indicators of whether integration is proceeding smoothly or hiding early stress.
Disclaimer: This post features ChartAlert-AI-generated financial content which may contain inaccuracies or errors. This commentary is strictly for informational purposes and does not constitute a recommendation to buy or sell any security. Investors are responsible for performing their own due diligence; always consult with a licensed financial advisor before making investment decisions.
Beyond the Price Action: Fundamental Analysis is Coming to ChartAlert
ChartAlert is evolving into integrated research with a future update that will embed fundamental data into your workflow. Alongside technical analysis, the new release will allow access to financial data, quarterly results review, earnings call transcripts, and valuation tools, connecting price action with corporate performance for smarter, data‑driven decisions.